Editorial: Has the time come for a new definition of microalbuminuria?

Current Vascular Pharmacology

Volumn 6, Issue 2, 2008, Pages 81-83

  Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b   Tziomalos, Konstantinos ^a,b   Kakafika, Anna I ^a   Athyros, Vasilios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular risk; Microalbuminuria

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; EDITORIAL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LOW DRUG DOSE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; URINARY EXCRETION; URINE LEVEL; WAIST CIRCUMFERENCE; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REFERENCE VALUE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; REFERENCE VALUES; RISK FACTORS;

EID: 47249100688     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783955329     Document Type: Editorial

References (46)

1. Deckert T, Yokoyama H, Mathiesen E, Rorm B, Jensen T, Feldt-Rasmussen B, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996; 312: 871-4.
2. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
3. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-3.
4. Cerasola G, Cottone S, D'Ignoto G, Giasso L, Mangano MT, Carapelle E, et al. Micro-albuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens Suppl 1989; 7: S332-3.
5. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.
6. Cao JJ, Barzilay JI, Peterson D, Manolio TA, Psaty BM, Kuller L, et al. The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the Cardiovascular Health Study. Atherosclerosis 2006; 187: 372-7.
7. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000; 23 Suppl 2: B35-9.
8. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. HOPE Study Investigators. Albuminuria and-risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
9. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy, individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am. J Kidney Dis 2003; 42: 466-73.
10. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
11. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.
12. Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, et al. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 2007; 255: 27-34.
13. Boelter MC, Gross JL, Canani LH, Costa LA, Lisboa HR, Tres GS, et al. Proliferative diabetic retinopathy is associated with microalbuminuria in patients with type 2 diabetes. Braz J Med Biol Res 2006; 39: 1033-9.
14. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, et al. DESIR Study Group. Waist circuference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006; 24: 1157-63.
15. Pambianco G, Costacou T, Orchard TJ. The Prediction of Major Outcomes of Type 1 Diabetes: A 12 year prospective evaluation of three separate definitions of the Metabolic Syndrome, and their components and estimated glucose disposal rate: The Pittsburgh Epidemiology of Diabetes Complications Study Experience. Diabetes Care 2007; 30: 1248-54.
16. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-59.
17. Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The consomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guys Hosp Rep 1969; 118: 247-54.
18. Svendsen PA, Oxenboll B, Christiansen JS. Microalbuminuria in diabetic patients-a longitudinal study. Acta Endocrinol Suppl (Copenh) 1981; 242: 53-4.
19. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-2.
20. Mogensen CE, Cbachati A, Christensen CK, Close CF, Deckert T, Hommel E, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985-1986; 9: 85-95.
21. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006; 15: 631-6.
22. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1): S79-S83.
23. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindhohn LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
24. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflaminatory cytokines. Exp Clin Endocrinol Diabetes 2007; 115: 38-41.
25. Choi HS, Sung KC, Lee KB. The prevalence and risk factors of microalbuminuria in normoglycemic, normotensive adults. Clin Nephrol 2006; 65: 256-61.
26. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
27. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoom Study. Kidney Int Suppl. 2004; 92: S42-4.
28. Cottone S, Mule G, Nardi E, Lorito MC, Guarneri M, Arsena R, et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 2007; 21: 167-72.
29. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H. et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-5.
30. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 33-7.
31. Klausen KP, Scharling H, Jensen JS, Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-7.
32. Wang TJ, Evans JC, Meigs JB, Rifal N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370-6.
33. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
34. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose glucose control with sulplunylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
35. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus; and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-9.
36. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
37. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type-2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
38. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8.
39. Tonelli M. Do statins protect the kidney by reducing proteinuria? Ann Intern Med 2006; 145: 147-9.
40. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
41. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
42. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-24.
43. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
44. Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes-data from the National Diabetes Register in Sweden. Diabetes Metab 2004; 30: 261-8.
45. Hansen HP, Gaede PH, Jensen BR, Parving HH. Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000; 23: 1742-5.
46. Perkins BA, Ficociello LH, Silva KH, Finkelstein DK Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-93.